LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
- None.
- None.
To participate by telephone, please dial (888) 259 6580 (Domestic) or (206) 962 3782 (International). The conference ID number is 48034263. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223135128/en/
Thomas R. Staab, II, CFO
ir.contact@lensar.com
Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com /
cradinovic@burnsmc.com
Source: LENSAR, Inc.
FAQ
When will LENSAR, Inc. release its fourth-quarter and full-year 2023 financial results?
What is the ticker symbol for LENSAR, Inc.?